{"page_content": "Standard Operating Procedure SOP-R4A-1.1 Page: 1 of 5 Version: Valid from: 1.0 March, 15 2024 Drugs combination screening\n\nCreated by Controlled by Approved by Name A. Federica Iannelli A. Francesca A.Alfredo Budillon \u2013 Bruzzese B. Elena Di Gennaro B. Maria Serena Roca C. Laura Grumetti Date 14.03.2024 14.03.2024 14.03.2024 Signature\n\nIndex\n\nIndex Goal and Area of Application... cece ccecseeseseseeceescsseecaesesseecsesesaesseesesseasessessesaeecae 2 Definitions and Abbreviations ..........ccccceccesseesssssecsecsececeecescessesaesseseeecaecaeseesesesseesueseseeseaes 2 Devises, Materials and Reagent ..0......ccecceccesssssseseeseeseesesceseeceecaecaeeeeseeseeaeaeeaeeeseeceecaeeaeeees 2 3.1 DeViSCS ....eeecceccescessesseeseeseecsecsecsecescessessessessesceecaecsecseceseessesuesseseecaecaecaeseseesaesaeeaeseesaes 2 3.2 Materials ......cccccccccessesssescessecsecsecescescessessecseeceecaecseceeceseessesaesseseecaecaeseeseeeesaesaeseseeaes 3 3.3 Reagents 0... ececescesceeceeceecseseeseesesaesceseesceecsecaeceeseesesaeaeeaeesceecaecaeceeeeeeeeaeaaeaeeeseesaeeaeearenes 3 Preliminary Procedures... cesses cesses ce cecseesseceescsseeceeseseeecaesesaeecsesesaseseesessesaeesasensaees 4 AL Cell number definition ..........cccccscccsecsecsecseceecescesseseseeceecaecaeceeceecessesaeseeeeesaeeneeeeenes 4 4.2 Drug dosage curve definition... ccc eee ceseeeeecaeeeeeecaetesseessesensesseesensessnecaeenee 5 PrOCEMUIE ooo. ee eeeeceececcescessessesseeeecsecaecsececessessessessesececaecseceeseseessesuesseseeecaecseseeseseessesueseseeseaes 5 Data Analisys occ cesessescseeessescaesessescsececscsseesessessecaesesseecaesesaesseesesseaseeseneesaecaee 9 ~~ Further applicable documents... cece cesses ceeseseeceesessescaesesaeecaenesaeesseseesesseesenseseeeeaee 9\n\n1 Goal and Area of Application ............................................................................................ 2\n\n2 Definitions and Abbreviations ........................................................................................... 2\n\n3 Devises, Materials and Reagents ....................................................................................... 2\n\n3.1 Devises ........................................................................................................................ 2\n\n3.2 Materials ..................................................................................................................... 3\n\n3.3 Reagents ...................................................................................................................... 3\n\n4 Preliminary Procedures...................................................................................................... 4\n\n4.1 Cell number definition ................................................................................................ 4\n\n4.2 Drug dosage curve definition...................................................................................... 5\n\n5 Procedure ........................................................................................................................... 5\n\n6 Data Analisys ..................................................................................................................... 9\n\n7 Further applicable documents ............................................................................................ 9\n\n1\n\nStandard Operating Procedure SOP-R4A-1.1 Page: 2 of 5 Version: Valid from: 1.0 March, 15 2024 Drugs combination screening", "metadata": {"doc_id": "b5c9e443-70ff-40b2-811f-452651ec9d7a", "content_type": "CompositeElement", "filename": "SOP-INT-NA-1_3 Drug combination screening.pdf"}}